OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OKYO Pharma (Nasdaq: OKYO) filed its Annual Report on Form 20-F for the year ended March 31, 2026, and reported a strengthened cash position supporting its late-stage development plans.

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) filed its Annual Report on Form 20-F for the year ended March 31, 2026, and reported a strengthened cash position supporting its late-stage development plans. According to the company, it raised approximately $25 million during the fiscal year, including a February 2026 public offering generating about $22 million in gross proceeds.

OKYO reported cash and cash equivalents of roughly $20.6 million at March 31, 2026, which it expects will fully fund the FDA-agreed global Phase 3 NEPTUNE pivotal trial of urcosimod in neuropathic corneal pain. NEPTUNE, planned to start in the second half of 2026, will enroll about 111 patients in the US and Europe, randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen and is designed as a potential registrational study following positive FDA Type D feedback.

Positive

• $25 million total capital raised during fiscal year ended March 31, 2026
• February 2026 public offering generated about $22 million in gross proceeds
• Cash and cash equivalents of approximately $20.6 million at March 31, 2026
• Company expects to be fully funded through completion of Phase 3 NEPTUNE trial
• FDA-agreed global Phase 3 NEPTUNE design with potential single-trial approval pathway
• NEPTUNE trial to enroll about 111 patients with 2:1 urcosimod-to-placebo randomization

Negative

• None.

Argus Jul 20 session 3 alerts

-4.20% close to close 3.1x rel. volume Open Argus

Details

News Market Reaction – OKYO

$75.05M Market Cap

On Jul 20, the day this news came out, OKYO closed 4.20% below the previous close. Our momentum scanner recorded 3 alerts for this stock that day. Relative volume reached 3.1x the daily average during tracking.

Data tracked by StockTitan Argus for the Jul 20 session.

Key Figures

Annual capital raised: $25 million Public offering proceeds: $22 million Cash and cash equivalents: $20.6 million +4 more

Annual capital raised

$25 million

Fiscal year ended March 31, 2026

Public offering proceeds

$22 million

February 2026 gross proceeds including overallotment

Cash and cash equivalents

$20.6 million

As of end of March 2026

Trial enrollment

111 patients

NEPTUNE global Phase 3 pivotal trial

Randomization

2:1

Urcosimod versus placebo in NEPTUNE

Urcosimod dose

0.05%

Single-dose NEPTUNE regimen

Trial initiation

Second half of 2026

Planned NEPTUNE initiation

Previous Clinical trial Reports

5 past events · Latest: Jul 08

Same Type 5 events

1. Jul 08

   Phase 3 FDA feedback

   24h Move

   -5.1%

   Positive FDA Type D feedback supported NEPTUNE Phase 3 design and registration pathway.

2. Mar 18

   Phase 2 quality data

   24h Move

   +1.3%

   Phase 2a quality-of-life improvements exceeded placebo across several patient-reported domains.

3. Jan 30

   Phase 2 presentation

   24h Move

   +0.5%

   Phase 2 urcosimod results were accepted for presentation at the ASCRS Annual Meeting.

4. Dec 11

   Phase 2 nerve outcomes

   24h Move

   +6.9%

   Exploratory corneal nerve imaging showed directionally favorable structural outcomes.

5. Sep 22

   Registration pathway trial

   24h Move

   +13.6%

   Company announced a 100-patient trial following reported Phase 2 pain-reduction results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, phase 3 pivotal trial, g-protein-coupled-receptor

3 terms

form 20-f regulatory

"filing of its Annual Report on Form 20-F for the fiscal year ended"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

phase 3 pivotal trial medical

"completion of the recently FDA-agreed global Phase 3 pivotal trial"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

g-protein-coupled-receptor technical

"agonist of the ChemR23 G-protein-coupled-receptor"

A G-protein-coupled receptor is a protein on the surface of a cell that acts like an antenna or doorbell, sensing molecules outside the cell and triggering internal responses. These receptors are the target for many medicines because turning them on or off can change how a cell behaves, so they matter to investors as common drug targets where successful therapies can create substantial revenue and affect a company’s clinical and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SEC’s website and the Company’s investor relations page. In conjunction with the filing, the Company provided a positive corporate update on its financial strength and clinical momentum.

“We are pleased to announce the filing of our annual report, which reflects substantial progress across our operations,” said Keeren Shah, Chief Financial Officer of OKYO Pharma. “During the year we raised approximately $25 million, including the recent capital raise backed by renowned investment funds, which has strengthened our cash position and provides us with ample financial resources to complete the NEPTUNE Phase 3 pivotal trial for urcosimod. This advances us toward potential registration, creating long-term value for patients and shareholders.”

Recent Capital Raise Backed by Renowned Investment Funds
OKYO Pharma successfully completed a public offering in February 2026 raising approximately $22 million in gross proceeds (including an overallotment), supported by strong participation from renowned investment funds and institutional investors. This capital infusion has significantly bolstered the Company’s balance sheet.

Robust Cash Position Enables Completion of Phase 3 Pivotal Trial
The strengthened financial position, with cash and cash equivalents of approximately $20.6 million as of end of March 2026, provides OKYO with the resources to be fully funded through the completion of the recently FDA-agreed global Phase 3 pivotal trial for its lead candidate urcosimod in NCP, positioning the Company for key upcoming milestones.

Overview of the NEPTUNE Clinical Trial
OKYO is advancing the NEPTUNE trial (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global Phase 3 pivotal study planned for initiation in the second half of 2026. The trial will enroll approximately 111 patients in the US and Europe, randomized 2:1 to receive 0.05% urcosimod or placebo in a single-dose regimen. Supported by positive FDA feedback from a Type D meeting, NEPTUNE is designed as a potential registrational study that could support an efficient single-trial approval pathway.

About Urcosimod

OKYO’s lead candidate, urcosimod, is a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled-receptor which is typically found on immune cells of the eye responsible for the ocular inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has demonstrated ocular analgesic and anti-inflammatory pharmacologic activity through its dual mechanism of action, supporting its therapeutic potential to address the significant unmet medical need for patients with neuropathic corneal pain.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2026. The company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements, except as may be required by law.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OKYO Pharma (NASDAQ: OKYO) announce in its July 20, 2026 annual report filing update?

OKYO Pharma announced the filing of its Form 20-F for the year ended March 31, 2026 and highlighted stronger cash resources. According to OKYO Pharma, this position is expected to fund completion of its FDA-agreed global Phase 3 NEPTUNE pivotal trial of urcosimod in neuropathic corneal pain.

How much capital did OKYO Pharma (OKYO) raise to support its Phase 3 NEPTUNE trial?

OKYO Pharma reports raising approximately $25 million during the fiscal year, including a February 2026 public offering of about $22 million in gross proceeds. According to OKYO Pharma, this strengthened balance sheet and cash of roughly $20.6 million are expected to fully fund the NEPTUNE Phase 3 trial.

What is the design of OKYO Pharma’s NEPTUNE Phase 3 trial for urcosimod in neuropathic corneal pain?

NEPTUNE is a global Phase 3 pivotal study planned for the second half of 2026, enrolling about 111 patients. According to OKYO Pharma, patients in the US and Europe will be randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen.

Why is the NEPTUNE Phase 3 trial potentially important for OKYO Pharma (NASDAQ: OKYO) investors?

NEPTUNE is designed as a potential registrational study that could support a single-trial approval pathway for urcosimod. According to OKYO Pharma, this design follows positive FDA Type D feedback and aims to advance urcosimod toward potential registration in neuropathic corneal pain.

What cash position did OKYO Pharma report as of March 31, 2026, and how will it be used?

OKYO Pharma reported cash and cash equivalents of approximately $20.6 million as of March 31, 2026. According to OKYO Pharma, this strengthened cash position is expected to fully fund the recently FDA-agreed global Phase 3 NEPTUNE pivotal trial for urcosimod in neuropathic corneal pain.

What is urcosimod, OKYO Pharma’s lead candidate in the NEPTUNE Phase 3 trial?

Urcosimod is described as a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled receptor. According to OKYO Pharma, it has shown ocular analgesic and anti-inflammatory pharmacologic activity, supporting its potential to address unmet needs in neuropathic corneal pain.

When will OKYO Pharma (OKYO) start the NEPTUNE Phase 3 trial and where will patients be enrolled?

OKYO Pharma plans to initiate the NEPTUNE Phase 3 trial in the second half of 2026, enrolling around 111 patients. According to OKYO Pharma, enrollment will occur across the US and Europe with urcosimod versus placebo in a single-dose regimen.